Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
<p>Abstract</p> <p>Background</p> <p>Dovitinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptors and platelet-derived growth factor receptor β. Dovitinib is currently in clinical tria...
Main Authors: | Chen Zhi-Yuan, Shi Ming, Peng Li-Xia, Wei Wei, Li Xin-Jian, Guo Zhi-Xing, Li Shu-Hong, Zhong Chong, Qian Chao-Nan, Guo Rong-Ping |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-12-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://www.translational-medicine.com/content/10/1/245 |
Similar Items
-
A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma
by: AlRabiah H, et al.
Published: (2020-01-01) -
Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
by: Johanna Weiss, et al.
Published: (2014-12-01) -
Dihydrodiosgenin inhibits endothelial cell-derived factor VIII and platelet-mediated hepatocellular carcinoma metastasis
by: Zhuang M, et al.
Published: (2019-05-01) -
AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma
by: Zong-Tao Chai, et al.
Published: (2021-05-01) -
Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma
by: Zhuo Yu, et al.
Published: (2022-01-01)